Arriva Pharmaceuticals : Protein Production Patent

1 October 2008 - Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti-inflammatory therapies, announced that it had been granted a patent in the U.S. for methods to produce certain proteins in yeast. Among the proteins whose production is covered by the patent (United States Patent 7,419,801) is recombinant alpha 1-antitrypsin (rAAT), the protein used in Respriva™, the company’s lead product.

“This patent extends our patent portfolio and strengthens our intellectual property estate for Respriva™,” said Sue Preston, chief executive officer of Arriva. “As we move forward with the development of Respriva™, we have multiple competitive advantages that leave us well positioned in the global market.”

Respriva™ is an inhaled rAAT. Arriva is currently conducting clinical trials with Respriva™ as replacement therapy in hereditary emphysema (HE). Patients with HE have a congenital deficiency in naturally occurring alpha 1-antitrypsin (AAT). Respriva™ also has the potential to ameliorate lung disease in other indications, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis... [PDF] Arriva Pharmaceuticals' Press Release -

Arriva Pharmaceuticals Granted Fusion Protein Patent

May 21, 2008 - Intellectual Property Provides Strong Position for Development of Therapy for Asthma- Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti-inflammatory therapies, announced today that it had been granted a patent in the U.S. related to a fusion protein with potential applications for treating respiratory diseases. The patent (United States Patent 7,247,704) covers compositions of matter and uses of Aeriva™, a fusion protein that combines Secretory Leukocyte Protease Inhibitor (SLPI) and recombinant alpha 1-antitrypsin (rAAT)... [PDF] Arriva Pharmaceuticals' Press Release -

Arriva Pharmaceuticals : Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema

Feb. 28, 2008 - Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti- inflammatory therapies for treating respiratory diseases, completed a financing of 6 million USD led by new Investor Nordic Biotech II K/S and with participation by MPM BioVentures. Since its founding in 1997, Arriva has now raised a total of 81 million USD.
"Key financing from Nordic Biotech II KS and from our earlier lead investor, MPM Capital, allows us to continue the development of recombinant alpha-one antitrypsin for hereditary emphysema," said Sue Preston, CEO, Arriva Pharmaceuticals. "With a committed, experienced management team, we are now focused on the clinical development of our lead and pipeline products."... [PDF]Arriva Pharmaceuticals' Press Release -